VRCA - Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11 2023 | Benzinga
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a virtual KOL event discussing the approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum on Wednesday, October 11, 2023 at 11:00 AM ET. To register, click here.
The event will feature Mark Kaufmann, MD (Advanced Dermatology, Miami), Michael Cameron, MD (Cameron Dermatology; Department of Dermatology, Mount Sinai, NY), and Mercedes Gonzalez, MD (Pediatric Dermatology of Miami) who will discuss the unmet medical need for patients suffering from molluscum contagiosum (molluscum), a highly contagious viral skin disease that affects approximately six million people — primarily children — in the United States.
The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of the body or to other people, including siblings. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to five years.
A live question and answer session will follow the formal presentation.
About Mark Kaufmann, MD
Dr. Kaufmann is Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery, which is a premier dermatology and cosmetic surgery practices with 160+ locations in the U.S. He is also an Associate Clinical Professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City, a position he has held since 1995. He was in solo private practice for 23 years until he joined The Dermatology Group in November 2017. In September 2020, he joined Advanced Dermatology and Cosmetic Surgery as their Chief Medical Officer. He received his medical degree from New York University School of Medicine, completing residency training in dermatology at the Albert Einstein College of Medicine in the Bronx, New York. He is Board Certified in Dermatology. Dr. Kaufmann is a former President of the American Academy of Dermatology (March 2022 until March 2023) and he has also served on the AAD Board of Directors. He has served on countless AAD committees and has chaired many of them as well. He also serves as an advisor to the Academy RUC team (Relative Value Scale Update Committee) - a position he has held for over a decade. Dr. Kaufmann's contributions ...